Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844672 | 0.91 | SIRT1 (0.53) | PPARDSLC6A9SIRT1CHRNA7 | |
| Hydrochloric Acid SCHEMBL10467836 | 0.90 | SIRT1 (0.52) | PPARDSLC6A9SIRT1CHRNA7 | |
| SCHEMBL27989609 | 0.89 | SRD5A1 (0.50) | PPARDSLC6A9SRD5A1MTNR1ACYP19A1 | |
| SCHEMBL19002290 | 0.88 | MTNR1A (0.51) | PPARDSLC6A9SRD5A1MTNR1ACYP19A1 | |
| SCHEMBL1842495 | 0.88 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL30746730 | 0.88 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL19469507 | 0.86 | MTNR1A (0.50) | PPARDSLC6A9SRD5A1MTNR1ACYP19A1 | |
| Hydrochloric Acid SCHEMBL9628615 | 0.86 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL19002833 | 0.84 | MTNR1A (0.47) | PPARDSLC6A9SRD5A1MTNR1ACYP19A1 | |
| SCHEMBL19002298 | 0.84 | PPARD (0.46) | PPARDSLC6A9SRD5A1MTNR1ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| EP-0275104-B1 | Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor | FERRER INT (ES) | 1994-01-19 | — | — | EP | disclosed |
| US-4843165-A | Process for preparing a 2,3-dihydro-1H-imidazolyl-ethoxy indene antithrombotic agent and its pharmaceutically acceptable salts | FERRER INTERNACIONAL S.A. (ES) | 1989-06-27 | — | — | US | disclosed |
| EP-0275104-A2 | Process for preparing 2,3-dihydro-1H-imidazolylalkoxyindene derivatives and pharmaceutically acceptable salts, and intermediate therefor | FERRER INTERNACIONAL, S.A. (ES) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | PPARD 1253/4885SLC6A9 4506/4885SRD5A1 1769/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | PPARD 1484/4885SLC6A9 3996/4885SRD5A1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.